San Diego-based Hanabusa IVF and Asian Egg Bank have been acquired by CSG.BIO, a global life sciences platform with capabilities across fertility, reproductive health, biologic preservation, and family-building services. Financial terms were not disclosed.
Hanabusa IVF is known for its individualized approach to fertility care, including mini-IVF and lower-stimulation treatments. Asian Egg Bank has become a leading resource for intended parents and clinics seeking access to Asian donor eggs. The acquisition complements CSG.BIO’s existing fertility practice, Connecticut-based New England Fertility Institute, and its broader preservation network that includes CryoChoice, AlphaCord, and CellSave.
“Joining CSG.BIO gives us the opportunity to build on what makes Hanabusa IVF and Asian Egg Bank so distinctive while gaining the strength of a broader global platform,” said Peter Fuzesi, CEO of Hanabusa IVF and Asian Egg Bank. “We see strong alignment between our mission and CSG.BIO’s capabilities across fertility, preservation, and family-building services. This next step allows us to continue advancing personalized care in San Diego while expanding what we can offer patients, intended parents, and partners around the world.”
The deal positions CSG.BIO with fertility clinics on both coasts and creates infrastructure connecting reproductive services, donor programs, biologic storage, and surrogacy and third-party reproduction services under one platform – reflecting the broader consolidation trend in the fertility industry as companies build end-to-end reproductive care networks.
